- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
- Interventions
- GRT-C903, GRT-R904, nivolumab, ipilimumab
- Biological
- Lead sponsor
- Gritstone bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 1,666
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Healthy Participants
- Interventions
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- Type 2 Diabetes
- Interventions
- Mulberry Leaf Extract, Placebo
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Molly Center Diabetes Care Guide (Paper-based), Tablet based interactive diabetes education modules
- Other
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
- Interventions
- Technosphere® Insulin, Usual Care
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 12
- States / cities
- Mission Hills, California • San Diego, California • Palm Harbor, Florida + 8 more
- Conditions
- Ameliorating Oxidative Stress in Type 1 Diabetes
- Interventions
- N-acetyl cysteine, omega 6 Fish oil ( PUFA), Placebo
- Drug · Dietary Supplement
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Mylan's insulin glargine, Lantus®
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 39
- States / cities
- Fresno, California • Greenbrae, California • La Jolla, California + 36 more
- Conditions
- Type 1 Diabetes, Hyperglycemia, Postprandial
- Interventions
- Insulin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 3 Years to 10 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Type 1 Diabetes Mellitus, Older Adults, Hypoglycemia
- Interventions
- eCGM (enhanced CGM)
- Other
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cystic Fibrosis, Inflammatory Bowel Disease, Type 1 Diabetes, Chronic Disease Management
- Interventions
- MD2ME
- Behavioral
- Lead sponsor
- Huang, Jeannie, M.D.
- Individual
- Eligibility
- 14 Years to 22 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Diabetic Neuropathy
- Interventions
- Placebo, Pulsatile IV insulin delivery (humalog, humulin, novolog)
- Procedure
- Lead sponsor
- Florida Atlantic University
- Other
- Eligibility
- 20 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- insulin degludec, insulin glargine, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 9
- States / cities
- Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- EMR-based BPA model, Placebo (EMR-based without BPA model)
- Other · Behavioral
- Lead sponsor
- T1D Exchange, United States
- Other
- Eligibility
- 2 Years to 95 Years
- Enrollment
- 1,178 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Hydrolysed infant formula, Nonhydrolysed infant formula
- Dietary Supplement
- Lead sponsor
- University of Helsinki
- Other
- Eligibility
- Up to 7 Days
- Enrollment
- 5,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2017
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Pittsburgh, Pennsylvania
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Psychosocial Survey Questionnaires
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- Afrezza Dose 1, Afrezza Dose 2
- Combination Product
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Escondido, California • Walnut Creek, California
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Combination Radiation, Immunotherapy, Surgery
- Combination Product
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Baltimore, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- 2nd Gen LabPatch Glucose Sensing System
- Device
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes, Monogenic Diabetes
- Interventions
- Metformin Extended Release Oral Tablet, Sitagliptin
- Drug
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- Up to 85 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type1 Diabetes
- Interventions
- 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
- Drug
- Lead sponsor
- Immunomolecular Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Aurora, Colorado • Renton, Washington
- Conditions
- Type 1 Diabetes
- Interventions
- Lantus and short acting analogs Vs NPH and short acting analogs
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 1 Diabetes Mellitus, Hypoglycemia, Hypoglycemia Unawareness
- Interventions
- Islet transplantation
- Biological
- Lead sponsor
- Rodolfo Alejandro
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida